{"entity":{"id":"nct07008703","kind":"trial","name":"Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain","aka":[],"tldr":"A phase 1/2 trial of Injection of humanized nerve growth factor (NGF) antibody in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.","summary":"Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain is a phase 1/2 interventional study registered as NCT07008703 by Shenyang Sunshine Pharmaceutical Co., LTD., with 132 participants planned, started 2024-03-27 and due to reach its primary completion in 2025-12. Interventions recorded: Injection of humanized nerve growth factor (NGF) antibody.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07008703","url":"https://clinicaltrials.gov/study/NCT07008703"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07008703","phase":"1/2","setting":"Phase Ib/IIa Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetic Characteristics of SSS40 in Subjects With Moderate to Severe Bone Metastasis Cancer Pain","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","enrolled":132,"outcomes":[]},"route":"/trials/nct07008703/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}